DDrare: Database of Drug Development for Rare Diseases

17. 多系統萎縮症
［臨床試験数：107，薬物数：153（DrugBank：48），標的遺伝子数：59，標的パスウェイ数：104］

Searched query = "Multiple system atrophy", "MSA-C", "MSA-P", "Olivopontocerebellar atrophy", "OPCA", "Striatonigral degeneration", "Shy-Drager syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 1) Inosine 5'-monophosphate; 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one; 11C-methylreboxetine; 13N-Ammonia; 18F-Dopa; 18F-Dopamne; AFFITOPE® PD01A + Adjuvant; AFFITOPE® PD03A + Adjuvant; AZD3241; AZD3241 100mg; AZD3241 300mg; AZILECT; AZILECT 1 mg comprimidos; Adjuvant without active component; Ammonia; Ampreloxetine; Ampreloxetine chydrochloride; Ampreloxetine hydrochloride; Angiotensin; Angiotensin-(1-7); Anti-Parkinson medication; Atomexetine; Autologous mesenchymal stem cells; Azilect; BHV-3241; BHV-4157; BIIB101; BOTULINUM TOXIN TYPE A; BQ123; Behavioral: BCI-FIT active querying; Behavioral: BCI-FIT adaptive signal modeling; Behavioral: BCI-FIT language modeling; Behavioral: BCI-FIT multi-modal access; Behavioral: Clinical characteristics of AMS patients; Behavioral: Conservative Measures for Orthostatic Hypotension; Behavioral: MOntreal Cognitive Assessment (MoCA); Blood sampling; Botulinum toxin type A; Bq123; Bydureon; CS10BR05; Captopril; Carbidopa; Carbidopa 200mg oral dose; Carbonate; DMI; DOPS; DaTSCAN™ Ioflupane (123I) Injection; DaTscan; Datscan; Desipramine; Desipramine (DMI); Device: Abdominal compression; Device: Deep Brain Stimulation; Device: sham compression; Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau; Diagnostic Test: Flutemetamol F18 Injection; Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau; Diagnostic Test: [18F]-RO6958948; Domperidone; Droxidopa; EGCG; EGCG as putative neuroprotective agent; Emeramide; Entacapone; Entacapone 400mg oral dose; Exenatide; Exenatide Pen Injector [Bydureon]; FLUOXETINE; Fipamezole; Fipamezole hydrochloride; Fipamezole hydrochloride 30 mg oral disintegrating tablets; Fipamezole hydrochloride 60 mg oral disintegrating tablets; Fipamezole hydrochloride 90 mg oral disintegrating tablets; Fludrocortisone; Flumazenil; Fluoxetine; Fluoxétine; Flutemetamol; Flutemetamol F18; GREEN TEA LEAF; Gold; Green Tea; Green tea leaf; Homeostasis Model Assessment of insulin resistance (HOMA); Hydrogen; IUPAC name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one; IVIg; Inosine; Intranasal Insulin; Intravenous immunoglobulin (IVIg); Intravesical injection of Botulinum A toxin; JP-1730/F01; JP-1730/F02; JP-1730/F03; L-Threo DOPS; LITHIUM CARBONATE; LITIO CARBONATO; Levodopa; Levodopa test; Lithium Carbonate; Lithium carbonate; Losartan; Metoprolol; Metoprolol tartrate 50 mg; Midodrine; Modal; N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE; NBMI; NT 101; Nebivolol; Nebivolol 5 mg; Nitrogen; Normal saline; Other: Abdominal compression; Other: Brain MRI (magnetic resonance imaging); Other: Sham abdominal compression; PROZAC; Procedure: Brain Magnetic Resonance Imaging (MRI); Procedure: determination of objective and subjective pain threshold; Pseudoephedrine; Pseudoephedrine + 480 ml water; Pseudoephedrine + 50 ml water; RASAGILINA MESILATO; Raclopride; Radiation: H215O PET; Radiation: PET (Positron Emission Tomography) Study; Rasagilina; Rasagiline; Rasagiline mesylate; Rifampicin; Riluzole; Rituximab; SAFINAMIDE; Safinamide; Safinamide Methanesulfonate; Safinamide methanesulfonate; Saline; Sildenafil25 mg; Sirolimus; Sirolimus 2 MG; Sunphenon EGCg; TD-9855; Tea leaf; Tllsh2910; Trimethaphan; Ubiquinol; Verdiperstat; Water; Xadago; Xeomin; [18F]FDOPA; [F-18]PBR06

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-003289-15-PL (EUCTR)	19/07/2019	07/05/2019	This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF)	A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine chydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	188	Phase 3	United States;Portugal;Czechia;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2018-003289-15-PL
(EUCTR)

19/07/2019

07/05/2019

This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF)

A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: TD-9855
INN or Proposed INN: ampreloxetine chydrochloride
Other descriptive name: TD-9855

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

188

Phase 3

United States;Portugal;Czechia;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand